Immunological and virological mechanisms of vaccine-mediated protection against SIV and HIV. - Wikidata - awgldk - TriplyDB

Immunological and virological mechanisms of vaccine-mediated protection against SIV and HIV.

Immunological and virological mechanisms of vaccine-mediated protection against SIV and HIV.

http://www.wikidata.org/entity/Q37625296

about

Approaches to preventative and therapeutic HIV vaccines HIV-Host Interactions: Implications for Vaccine Design Parsimonious Determination of the Optimal Infectious Dose of a Pathogen for Nonhuman Primate Models AAV-Delivered Antibody Mediates Significant Protective Effects against SIVmac239 Challenge in the Absence of Neutralizing Activity Progress in HIV-1 vaccine development.Bottlenecks in HIV-1 transmission: insights from the study of founder viruses Systems serology for evaluation of HIV vaccine trials.Survivors Remorse: antibody-mediated protection against HIV-1.Surrogates of protection in repeated low-dose challenge experiments.Immunologic and Virologic Mechanisms for Partial Protection from Intravenous Challenge by an Integration-Defective SIV Vaccine.HIV-1 vaccines: challenges and new perspectives Adenovirus prime, Env protein boost vaccine protects against neutralization-resistant SIVsmE660 variants in rhesus monkeys.Molecularly tagged simian immunodeficiency virus SIVmac239 synthetic swarm for tracking independent infection events Boosting of HIV-1 neutralizing antibody responses by a distally related retroviral envelope protein.The presence of glutamine at position 315 but not epitope masking predominantly hinders HIV subtype C neutralization by the anti-V3 antibody B4e8.Nonneutralizing functional antibodies: a new "old" paradigm for HIV vaccines The influence of delivery vectors on HIV vaccine efficacy First-in-human evaluation of a hexon chimeric adenovirus vector expressing HIV-1 Env (IPCAVD 002)Vaccine-induced plasmablast responses in rhesus macaques: phenotypic characterization and a source for generating antigen-specific monoclonal antibodies.Identification, molecular cloning, and analysis of full-length hepatitis C virus transmitted/founder genotypes 1, 3, and 4 Conserved molecular signatures in gp120 are associated with the genetic bottleneck during simian immunodeficiency virus (SIV), SIV-human immunodeficiency virus (SHIV), and HIV type 1 (HIV-1) transmission Comparison of Immunogenicity in Rhesus Macaques of Transmitted-Founder, HIV-1 Group M Consensus, and Trivalent Mosaic Envelope Vaccines Formulated as a DNA Prime, NYVAC, and Envelope Protein Boost Rationally Targeted Mutations at the V1V2 Domain of the HIV-1 Envelope to Augment Virus Neutralization by Anti-V1V2 Monoclonal Antibodies.Broadening of Virus-Specific CD8+ T-Cell Responses Is Indicative of Residual Viral Replication in Aviremic SIV Controllers Vaccine-Induced Linear Epitope-Specific Antibodies to Simian Immunodeficiency Virus SIVmac239 Envelope Are Distinct from Those Induced to the Human Immunodeficiency Virus Type 1 Envelope in Nonhuman Primates.Characterization and Implementation of a Diverse Simian Immunodeficiency Virus SIVsm Envelope Panel in the Assessment of Neutralizing Antibody Breadth Elicited in Rhesus Macaques by Multimodal Vaccines Expressing the SIVmac239 Envelope.Animal models in HIV-1 protection and therapy Targeted Isolation of Antibodies Directed against Major Sites of SIV Env Vulnerability.Breakthrough of SIV strain smE660 challenge in SIV strain mac239-vaccinated rhesus macaques despite potent autologous neutralizing antibody responses.Elite Control, Gut CD4 T Cell Sparing, and Enhanced Mucosal T Cell Responses in Macaca nemestrina Infected by a Simian Immunodeficiency Virus Lacking a gp41 Trafficking Motif.New prospects for a preventive HIV-1 vaccine.Structure and Recognition of a Novel HIV-1 gp120-gp41 Interface Antibody that Caused MPER Exposure through Viral Escape.Conserved signatures indicate HIV-1 transmission is under strong selection and thus is not a "stochastic" process Protective efficacy of adenovirus/protein vaccines against SIV challenges in rhesus monkeys.Breakthrough Virus Neutralization Resistance as a Correlate of Protection in a Nonhuman Primate Heterologous Simian Immunodeficiency Virus Vaccine Challenge Study.Single-Genome Sequencing of Hepatitis C Virus in Donor-Recipient Pairs Distinguishes Modes and Models of Virus Transmission and Early Diversification.Incorporating founder virus information in vaccine field trials.Signatures in Simian Immunodeficiency Virus SIVsmE660 Envelope gp120 Are Associated with Mucosal Transmission but Not Vaccination Breakthrough in Rhesus Macaques Evaluation of the maturation of individual Dengue virions with flow virometry.Novel Conserved-region T-cell Mosaic Vaccine With High Global HIV-1 Coverage Is Recognized by Protective Responses in Untreated Infection.

P2860

Q26764851-27BCE841-6C0C-4821-8F76-9F84C3A00968 Q26765966-445BFF6A-65D8-4FED-9BB4-D9360C752053 Q27318212-FB0F7E05-51BA-4DFF-A1BF-600AE87A7676 Q27318266-DA822DD6-325D-45C5-B096-7A8FB8A003EA Q27693849-A32A5B2B-E701-4718-84EC-B30B5F8B6E59 Q28082862-7E25402C-2033-48B9-AC47-43F316A8BD3C Q30238729-83B25C9C-1AA3-49EE-937B-956D1AF2A944 Q30238730-F4D884E9-1445-497E-980E-F61BC3476423 Q30371157-9879F885-E24E-4ED5-BA6B-B072887496D4 Q32183405-8FB54BAA-1398-4E52-A73A-74989813498C Q33577972-4431DEEC-F9C8-4B1D-88CC-967EEB770768 Q33780980-0233BFDB-31C2-4009-9BC8-ED62E5461FE7 Q33900353-06FDF014-377F-400A-9060-DDBAD5D44329 Q33955745-F030B2C7-281A-4FB7-AAC8-B144AFB58FCF Q34017550-5820657F-F491-408B-8E3E-02EED200D937 Q34057711-5955D946-5819-454D-B751-F0C19DD81443 Q34077543-9D366C43-7831-4E11-9E11-B20D1C60C0EA Q34209026-A969D45D-7B9D-4636-9578-E5AEAA016F4A Q35071821-98BB933D-1069-413A-A640-21FEF8302635 Q35172385-B22536C6-CA68-48CB-AB90-611203672C31 Q35488153-56DA5E42-74F8-4EA2-8DF5-0206A32A119B Q35760486-4B30A302-169E-47B0-A35A-243CD62217AA Q35817106-DBA69A40-A88F-4F13-8A13-5040C730BFC9 Q35831895-FA50D72C-ADBF-474C-B791-404351856D36 Q35914306-DF2EE6D1-404B-4728-A47F-CBCB89B1373C Q35914362-115E1746-8F3C-4A4D-8E8C-A5B8A1CE5058 Q35920037-CE295935-0ED6-4325-AE42-CA7C7A465BF3 Q35985519-42964061-91FE-45F6-BE37-C25A2025D312 Q36008380-E2439ECC-FF33-493D-B4CC-01197A56DD98 Q36086229-A27A911E-5B42-4110-B547-C725C4BC3521 Q36223864-2F761437-AEE5-4E00-8DB3-54424D15FB26 Q36246403-9FC19AC3-F0F0-4E21-8CC6-C2E97262642A Q36288959-E1A5AAD6-E99A-49AC-838A-8F2812072D6A Q36300153-20FDBC2E-75B6-4C78-BF6E-D2C23B9AA874 Q36334371-99628BEA-DADC-4CF5-846D-FEA0B2C004C3 Q36433960-FA5A2D90-165F-412E-810B-6C479EE77B1C Q36509005-1B8BD8AB-5F77-4345-A8D6-DA346F58E004 Q36523998-50C6AAA5-E4AF-4352-9B89-642CCDAEF581 Q36553879-1A15E1B1-39F3-4A39-90D3-4B0F0A9EBB20 Q36951283-73EA1FEB-DB60-4CD8-9F82-8F90686BB63A

P2860

Immunological and virological mechanisms of vaccine-mediated protection against SIV and HIV.

http://www.wikidata.org/entity/Q37625296

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 18 December 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Immunological and virological ...... rotection against SIV and HIV.

@en

Immunological and virological ...... rotection against SIV and HIV.

@nl

type

label

Immunological and virological ...... rotection against SIV and HIV.

@en

Immunological and virological ...... rotection against SIV and HIV.

@nl

prefLabel

Immunological and virological ...... rotection against SIV and HIV.

@en

Immunological and virological ...... rotection against SIV and HIV.

@nl

P1433

Q37625296-ED66C146-21BD-40A5-8C25-7E39DDFB54A0

P1476

Q37625296-F52BB46E-6E11-4E8C-B73F-A91D58CC165E

P2093

Q37625296-076DB550-CC04-44BE-8DA9-22A915158C56

Q37625296-17E78929-EB9A-4962-BB14-E39CA275E971

Q37625296-1AF28384-5E50-4D3C-83D5-108119FEBEB4

Q37625296-260349D5-1B45-4837-BFFE-3EF34C46DC70

Q37625296-2B292CD9-72F4-4950-88F2-4E94C2D467FB

Q37625296-39796890-A845-4F28-B8B9-F9329D0141FB

Q37625296-3EAABE38-6997-4D78-A937-7C10724FC915

Q37625296-5722F4D2-91C7-4CC8-96CC-86728F4A808A

Q37625296-60AB11D4-895C-405F-9806-16F0C294DA7A

Q37625296-702F2013-AB5D-4029-A82C-A596413AB72A

P2860

Q37625296-06EF3B34-6D5D-407A-9C19-B89C9D805690

Q37625296-08FA985C-6196-4331-98C1-5D2F57DAFF6D

Q37625296-131BF188-9DB7-48B5-A007-41F0E465AAA8

Q37625296-1BDC9801-982A-4ADB-B78C-B038D190887B

Q37625296-20B1C86D-6DDF-4DE6-B428-57EDCAEF1037

Q37625296-24272F8A-EC8F-44D5-8DEB-AF99A5C6097D

Q37625296-254B1570-65F1-4244-A083-768B82E4FEC1

Q37625296-2E612F53-6564-4ABF-96D3-D555E953D079

Q37625296-2E7EB236-E2BB-43CB-9CF0-FE9C3FA43AF6

Q37625296-2F59539F-F776-451F-B5E9-F739B48BD61C

P2888

Q37625296-1D41CF69-8041-4B00-8AB5-20F42E845676

P304

Q37625296-AD30B462-8508-4E8F-93EF-6258D162779D

P31

Q37625296-BE58FA6B-14A4-4B16-8B82-1E6854084262

P356

Q37625296-4FB97209-1028-432B-B80F-DE23310C8229

P407

Q37625296-106A2144-AB8B-4D0E-978B-D84F0AA878B4

P433

Q37625296-CAA45EE8-4EDB-4AF7-BDC2-9B16A2802871

P478

Q37625296-3032BEDC-3844-4E12-8CF4-37E4C9762E1B

P50

Q37625296-0C27E113-EB74-40BF-90B8-ABF42C931C55

Q37625296-14204027-A115-41AE-AFA7-09F37DC3D432

Q37625296-26DDE985-56F7-4C18-B889-0048551D0212

Q37625296-42A154CC-9F87-4C29-90AC-B5439D2A4294

Q37625296-7862C843-65D5-4BAB-8835-A9682023E01B

Q37625296-80F96344-581F-48B3-A3E1-F9B4CB1698F8

Q37625296-BA0B2B88-46E6-482A-A0BB-F3590760E5CE

Q37625296-BD313597-032C-49C0-80DA-B81D1E611855

Q37625296-F55FC84C-54C9-4844-B00C-4AFFB5746664

P577

Q37625296-C62A12E5-9D69-4A31-8B6A-10A56E9CC7D9

P5875

Q37625296-DD8517C7-554E-4F81-AB67-E240FC2909D3

P698

Q37625296-4067BAEA-0C77-4064-9C2E-67E31ECCEBA9

P921

Q37625296-63E1BE09-4F76-4813-A5C8-128A8774A803

Q37625296-FD3C0D98-BDD1-49CB-88B6-76FFF570876A

P932

Q37625296-1F2E5FBE-FE86-4452-807E-FE0D74C6793B

P356

P1433

P1476

Immunological and virological ...... rotection against SIV and HIV.

@en

P2093

Adam P Buzby

http://www.w3.org/2001/XMLSchema#string

Brandy M Ward

http://www.w3.org/2001/XMLSchema#string

Celia Labranche

http://www.w3.org/2001/XMLSchema#string

Georgia D Tomaras

http://www.w3.org/2001/XMLSchema#string

Hugh C Welles

http://www.w3.org/2001/XMLSchema#string

John-Paul M Todd

http://www.w3.org/2001/XMLSchema#string

Kathryn E Foulds

http://www.w3.org/2001/XMLSchema#string

Kelly E Seaton

http://www.w3.org/2001/XMLSchema#string

Ling Shen

http://www.w3.org/2001/XMLSchema#string

Linh V Mach

http://www.w3.org/2001/XMLSchema#string

P2860

Vaccine Induction of Antibodies against a Structurally Heterogeneous Site of Immune Pressure within HIV-1 Envelope Protein Variable Regions 1 and 2

TRIM5alpha Modulates Immunodeficiency Virus Control in Rhesus Monkeys

Prevention of infection by a granulocyte-macrophage colony-stimulating factor co-expressing DNA/modified vaccinia Ankara simian immunodeficiency virus vaccine

Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand

Immune-correlates analysis of an HIV-1 vaccine efficacy trial

Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies

Preclinical studies of human immunodeficiency virus/AIDS vaccines: inverse correlation between avidity of anti-Env antibodies and peak postchallenge viremia.

Assessing vaccine effects in repeated low-dose challenge experiments.

Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine.

A computational framework for the analysis of peptide microarray antibody binding data with application to HIV vaccine profiling

P2888

P304

502-508

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NATURE12893

http://www.w3.org/2001/XMLSchema#string

P407

P433

7484

http://www.w3.org/2001/XMLSchema#string

P478

505

http://www.w3.org/2001/XMLSchema#string

P50

David C Montefiori

P577

2013-12-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

259386998

http://www.w3.org/2001/XMLSchema#string

P698

24352234

http://www.w3.org/2001/XMLSchema#string

P921

P932

3946913

http://www.w3.org/2001/XMLSchema#string